[ad_1]
Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.
[ad_2]
Source link
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Published on:
More